Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 20/20 | 0.76 |
| ▸ | KCNK9 | Q9NPC2 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30417533 | 0.94 | KCNK3 (0.69) | KCNK3KCNK9 | |
| SCHEMBL29776787 | 0.92 | KCNK3 (0.77) | KCNK3KCNK9 | |
| SCHEMBL21826617 | 0.86 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL22636359 | 0.86 | KCNK3 (0.73) | KCNK3KCNK9 | |
| SCHEMBL29776789 | 0.86 | KCNK3 (0.91) | KCNK3KCNK9 | |
| SCHEMBL21826578 | 0.85 | KCNK3 (0.82) | KCNK3KCNK9 | |
| SCHEMBL22636354 | 0.83 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL25424018 | 0.82 | KCNK3 (0.81) | KCNK3KCNK9 | |
| SCHEMBL21826237 | 0.81 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL22635905 | 0.81 | KCNK3 (1.00) | KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452264-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118126-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118102-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| EP-3965766-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |